Rethinking CAR‑T Manufacturing Paradigms: Terminology, Operational Considerations, and Economic Trade‑Offs 

In this peer‑reviewed Cytotherapy publication, Eytan Abraham, PhD, CCO and CTO of Minaris, co‑authors a critical examination of how CAR‑T manufacturing must transform to meet the realities of scale, cost pressure, and global demand. As autologous cell therapies move from clinical innovation to commercial expectation, sponsors must rethink centralized and decentralized manufacturing models, automation strategies, and quality frameworks. This article provides a clear lens on the operational and economic trade‑offs that determine scalability, CMC strategy, and sustainable patient access, equipping biotech leaders, technical teams, and investors to make more informed manufacturing decisions.